论文部分内容阅读
目的探讨上皮性卵巢癌多药耐药（ＭＤＲ１）基因的表达及其临床意义。②方法利用逆转录聚合酶链反应（ＲＴ－ＰＣＲ）检测３３例初治上皮性卵巢癌病人肿瘤组织ＭＤＲ１基因表达情况，同时用ＭＴＴ比色法检测肿瘤细胞对抗癌药的敏感性。③结果１０例（３０．３％）卵巢癌病人ＭＤＲ１基因表达阳性。体外试验表明，ＭＤＲ１基因表达阳性卵巢癌细胞对多种抗癌药耐药，ＭＤＲ１基因的表达与卵巢癌细胞分化程度有关，但与病人的年龄、组织学类型及分期无关。④结论ＭＤＲ１基因的表达可作为判断卵巢癌病人预后的一个指标
Objective To investigate the expression of multidrug resistance (MDR1) gene in epithelial ovarian cancer and its clinical significance. Methods The expression of MDR1 gene in 33 cases of newly diagnosed epithelial ovarian cancer was detected by reverse transcription polymerase chain reaction (RT-PCR). The sensitivity of tumor cells to anticancer drugs was detected by MTT colorimetric assay. 3 Results MDR1 gene expression was positive in 10 cases (30.3%) of ovarian cancer patients. In vitro tests showed that MDR1 gene-positive ovarian cancer cells are resistant to various anticancer drugs. The expression of MDR1 gene is related to the degree of differentiation of ovarian cancer cells, but has nothing to do with the patient’s age, histological type and stage. 4 Conclusion The expression of MDR1 gene can be used as an indicator to predict the prognosis of ovarian cancer patients.